Literature DB >> 33728574

Self-perceived cognitive functioning and quality of life among cancer survivors: results from the PROFILES registry.

Simone Oerlemans1, Sanne B Schagen2,3, Corina J van den Hurk4, Olga Husson2,5, Dounya Schoormans6, Lonneke V van de Poll-Franse4,2,6.   

Abstract

PURPOSE: The aim was to investigate the level of self-perceived cognitive functioning and its associated factors among a large population-based cohort of cancer survivors and their matched controls.
METHODS: Data were obtained from population-based PROFILES registry cohorts, including colon, rectum, prostate or thyroid cancer, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia, multiple myeloma (MM), melanoma, or basal cell carcinoma (BCC)/squamous cell carcinoma (SCC). All patients completed the EORTC QLQ-C30 from which self-perceived cognitive functioning, fatigue, functioning, and global health status/quality of life (GHS/QoL) were used. The PROFILES registry data were linked with the Netherlands Cancer Registry to obtain sociodemographic and clinical data.
RESULTS: Six thousand seven hundred eighty-six survivors were included (response rate=76%). Survivors, except for melanoma and BCC/SCC, reported on average lower self-perceived cognitive functioning scores compared to their matched controls (all p's<0.01). Largest differences with the norm were observed in thyroid cancer, HL, NHL and MM, and younger survivors (<50 years). Survivors with lower emotional functioning and more fatigue were more likely to report impaired self-perceived cognitive functioning.
CONCLUSION: Self-perceived impaired cognitive functioning is prevalent among a wide range of cancer survivors, especially among survivors <50 years. Approaches targeting cognitive problems including attention for co-occurring symptoms such as fatigue and emotional impairments are needed to improve care for these patients. IMPLICATIONS FOR CANCER SURVIVORS: Cancer survivors and clinicians should be aware that impaired self-perceived cognitive functioning is a frequently reported consequence of cancer and its treatment among survivors of various cancer types. Clinicians can redirect survivors to a relevant healthcare provider or program to target cognitive problems.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anxiety; Cancer survivors; Cognitive functioning; Fatigue; Normative population; Quality of life

Mesh:

Year:  2021        PMID: 33728574     DOI: 10.1007/s11764-021-01023-9

Source DB:  PubMed          Journal:  J Cancer Surviv        ISSN: 1932-2259            Impact factor:   4.442


  2 in total

1.  Predictors of subjective versus objective cognitive functioning in patients with stable grades II and III glioma.

Authors:  Karin Gehring; Martin J B Taphoorn; Margriet M Sitskoorn; Neil K Aaronson
Journal:  Neurooncol Pract       Date:  2015-03-03

Review 2.  Use of the Distress Thermometer in Clinical Practice.

Authors:  Kristin K Ownby
Journal:  J Adv Pract Oncol       Date:  2019-03-01
  2 in total
  2 in total

1.  Measuring Clinical, Biological, and Behavioral Variables to Elucidate Trajectories of Patient-Reported Outcomes: The PROFILES Registry.

Authors:  Lonneke V van de Poll-Franse; Nicole Horevoorts; Dounya Schoormans; Sandra Beijer; Nicole P M Ezendam; Olga Husson; Simone Oerlemans; Sanne B Schagen; Geja J Hageman; Katrijn Van Deun; Corina van den Hurk; Mies van Eenbergen; Floortje Mols
Journal:  J Natl Cancer Inst       Date:  2022-06-13       Impact factor: 11.816

2.  Increased health-related quality of life impairments of male and female survivors of childhood cancer: DCCSS LATER 2 psycho-oncology study.

Authors:  Marloes van Gorp; Loes M E van Erp; Anne Maas; Leontien C M Kremer; Eline van Dulmen-den Broeder; Wim J E Tissing; Jacqueline J Loonen; Helena J H van der Pal; Andrica C H de Vries; Marry M van den Heuvel-Eibrink; Cécile M Ronckers; Dorine Bresters; Marloes Louwerens; Margriet van der Heiden-van der Loo; Gea A Huizinga; Heleen Maurice-Stam; Martha A Grootenhuis
Journal:  Cancer       Date:  2021-11-02       Impact factor: 6.921

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.